Shots: The expansion approval is based on the CA180-372 (NCT01460160) P-II study results assessing Sprycel (qd, 60 mg/m @24 mos.) + CT in 78 patients with Ph+ ALLaged 2 to 10 yrs. The P-II CA180-372 study demonstrated as an effective treatment with EFS binary rate 64.1% in patients with newly diagnosed B-cell precursor Ph+ ALL […]Read More
Shots: The CHMP (EMA) recommendation is based on P-II CA180-372 (NCT01460160) study assessing Sprycel + CT in pediatric patients with newly diagnosed +ve acute lymphoblastic leukemia (ALL) Sprycel received the US FDA’s and EU’s approval to treat pediatric patients with +ve chronic myeloid leukemia in chronic phase (CML-CP) in Nov, 2017 & July, 2018 respectively Sprycel is a tyrosine kinase inhibitor, […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
